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Abstract
Background: Chlamydia infection in acute pelvic inflammatory disease (PID) is associated with serious complications
including ectopic pregnancy, tubal infertility, Fitz-Hugh-Curtis syndrome and tubo-ovarian abscess (TOA). This study
compared clinical and laboratory data between PID with and without chlamydia infection.
Methods: The medical records of 497 women who were admitted with PID between 2002 and 2011 were reviewed.
The patients were divided into two groups (PID with and without chlamydia infection), which were compared in terms
of the patients’ characteristics, clinical presentation, and laboratory findings, including inflammatory markers.
Results: The chlamydia and non-chlamydia groups comprised 175 and 322 women, respectively. The patients in the
chlamydia group were younger and had a higher rate of TOA, a longer mean hospital stay, and had undergone more
surgeries than the patients in the non- chlamydia group. The erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), and CA-125 level were higher in the chlamydia group than in the non-chlamydia group, but there
was no significant difference in the white blood cell count between the two groups. The CA-125 level was the
strongest predictor of chlamydia infection, followed by the ESR and CRP level. The area under the receiving
operating curve for CA-125, ESR, and CRP was 0.804, 0.755, and 0.663, respectively.
Conclusions: Chlamydia infection in acute PID is associated with increased level of inflammatory markers, such as
CA-125, ESR and CRP, incidence of TOA, operation risk, and longer hospitalization.
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Background
Pelvic inflammatory disease (PID) is caused by colonization
of the endocervix by microorganisms, which then ascend to
the endometrium and fallopian tube. Inflammation can be
at any point along a continuum that includes endometritis,
salpingitis, and peritonitis [1]. PID, one of the most import-
ant infections in sexually active women of reproductive age,
is a major public health problem [2].
The polymicrobial etiology of PID can be delineated ar-
tificially into sexually transmitted infections that colonize
the upper genital tract, including Chlamydia trachomatis,
Neisseria gonorrhoeae, and endogenous microorganisms
found in the vagina, particularly anaerobic bacteria such
as Gardnerella vaginalis, Haemophilus influenzae, enteric
Gram-negative rods, and Streptococcus agalactiae [3, 4].
Chlamydia trachomatis is a Gram-negative bacterium
that infects the columnar epithelium of the cervix,
urethra, and rectum and a common bacterial cause of
sexually transmitted infections [5]. Chlamydia infection
is associated with a wide spectrum of upper genital tract
pathologies, ranging from asymptomatic endometritis to
symptomatic salpingitis, peritonitis, tubo-ovarian abscess
(TOA), Fitz-Hugh-Curtis syndrome (FHCS) character-
ized by inflammation in perihepatic capsules, and long-
term sequelae such as infertility, ectopic pregnancy, and
chronic pelvic pain [6–8]. Moreover, chlamydia infection
can lead to obstetric complications, including premature
rupture of the membrane, chorioamnionitis, premature
delivery, puerperal and neonatal infections, and an in-
creased risk of the development of cervical carcinoma [9].
Prompt treatment and screening for chlamydia infections
in women of reproductive age is essential to prevent se-
vere damage to the reproductive organs; Consequently,
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chlamydia screening and treatment programs have been
implemented in many countries [10].
A few studies on the comparison between chlamydia
and non-chlamydia infection in women with PID have
been reported; however, previous studies mainly fo-
cused on the comparisons of clinical characteristics and
sequelae [11–13].
This study compared the clinical course of PID with
and without chlamydia infection by examining patients’
clinical and laboratory data on admission.
Methods
Participants
We reviewed the medical records of 1,422 women diag-
nosed with PID, salpingitis, endometritis, FHCS, or a TOA,
who were treated at St. Vincent’s Hospital (Suwon, Korea)
between January 2002 and December 2011 with a diag-
nosis at discharge of PID, salpingitis, endometritis, or
TOA. This retrospective study was approved by the
Institutional Review Board of Catholic University of
Korea(C11RIMI0130V).
The definition of PID was based on a clinical history of
abdominal pain and on clinical findings of abdominal
pain, cervical motion tenderness, and adnexal tenderness.
In addition, at least one or more minor criterion was
required: temperature ≥38.3°C, an abnormal cervical or
vaginal mucopurulent discharge, an elevated erythrocyte
sedimentation rate (ESR) or C-reactive protein (CRP)
level, and laboratory documentation of a cervical infection
with Neisseria gonorrhoeae or Chlamydia trachomatis
[14]. All patients underwent pelvic ultrasonography or
abdominal and pelvic computed tomography (CT).
FHCS was indicated the following: (1) abdominal CT
showing pelvic inflammation with contrast enhancement
of hepatic capsules, or (2) adhesions between the liver and
the diaphragm or the liver and the anterior abdominal
wall as detected by laparoscopic surgery [15]. TOA was
diagnosed based on the presence of an abscess, indicated
by a tender adnexal mass or masses and ultrasonographic
or abdominal CT findings supporting an abscess. The
sonographic diagnosis of TOA was based on the demon-
stration of a complex, cystic mass with thick, irregular
walls, partitions, internal echoes, and absent peristalsis
[16]. The finding of TOA by CT was based on adnexal
wall thickening and enhancement with complex fluid col-
lections that may contain internal septa and a fluid-debris
level [17]. The diagnosis of TOA was based on satisfying
the PID criteria and the presence of at least one complex
pelvic mass as mentioned above for ultrasonographic or
CT findings [14].
Participants were excluded based on the following cri-
teria: (1) no assessment of the CA-125 level (n = 378);
(2) not performing vaginal swab for a chlamydia infec-
tion (n = 323); (3) not meeting the diagnostic criteria of
PID (n = 167); (4) the presence of a uterine or adnexal
pathology, including epithelial and germ cell ovarian
neoplasms, endometriosis, leiomyoma, or adenomyosis
(n = 30); (5) antibiotic use over the preceding 7 days
(n = 21); and (6) obstetric delivery or abortion in the
previous 30 days (n = 6). We measured the axillary
body temperature of all patients, with fever defined as
a temperature of ≥38°C. The white blood cell (WBC)
count for each patient was quantified using the XE-2100™
automated hematology system (Sysmex Inc., Mundelein,
IL, USA). The intra- and inter-assay coefficients of vari-
ation (CVs) were 1.7 and 1.9%, respectively. Leukocytosis
was defined as a WBC count greater than ≥11,000/mm3.
The serum ESR was measured using a modified version of
the Westergren method with a Test-1 automated analyzer
(Ailfax, Padova, Italy). The intra- and inter-assay CVs were
3.5 and 3.4%, respectively. The upper limit of normal for
the ESR in females ≤50 years of age is 20 mm/h [18]. The
serum CRP level was measured by a turbidimetric
immunoassay (TIA) using a Hitachi 7600-110® automatic
analyzer (Hitachi Co., Tokyo, Japan). The intra- and inter-
assay CVs were 5.4 and 2.7%, respectively. Normal serum
CRP levels range from 0 to 0.6 mg/dl. The serum CA-125
level was measured by a chemiluminescent microparticle
immunoassay (CMIA) using a CA-125 II™ kit (Abbott
Architect, Inc., Chicago, IL, USA). The intra- and inter-
assay CVs were 2.4 and 3.9%, respectively. CA-125 was
considered abnormal if the concentration was ≥35 IU/ml.
Endocervical swabbing and testing by real-time polymer-
ase chain reaction (PCR) were done to identify Neisseria
gonorrhoeae and Chlamydia trachomatis.
The two groups were compared statistically using a
two-tailed Student’s t-test and χ2 test. Logistic regression
analysis was performed to determine the relationship
between chlamydia infection in PID and inflammatory
markers. Since CA-125 is influenced by age, smoking and
pelvic pathology, the association between CA-125 and
chlamydia infection in PID was evaluated by logistic
regression analysis and analysis of covariance (ANCOVA).
The covariates were age, parity, histories of pelvic sur-
gery or cesarean section, use of intrauterine device (IUD),
menstrual problems, alcohol consumption, smoking, and
TOA. A receiver operating characteristic (ROC) curve ana-
lysis was used to determine the relationship between chla-
mydia infection in PID and inflammatory markers. p < 0.05
was considered to indicate statistical significance.
Results
Among the 497 females diagnosed with acute PID, 175
(35.2%) and 322 (64.8%) were in the chlamydia and
non-chlamydia groups, respectively. The patients in the
chlamydia group were younger than those in the non-
chlamydia group, and the patients in the chlamydia
group were less likely to be married and to have had
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children than those in the non-chlamydia group. There
were no significant differences between the groups re-
garding abortion, previous pelvic surgery, previous PID
episodes, IUD insertion, barrier contraceptive use, inci-
dence of menstrual problems, and alcoholic and smok-
ing history. The patients in the chlamydia group had
more symptom of right upper quadrant pain and the
patients in non-chlamydia group had more symptom of
lower abdominal pain (Table 1).
There were no significant differences in the mean
WBC count, leukocytosis, mean temperature, and
the incidence of fever between the two groups, while
the ESR, CRP, and CA-125 level were higher in the
chlamydia group than the in non-chlamydia group
(all P < 0.001; Table 2).
Logistic regression analysis was used to identify the
independent variables that affected the serum CA-
125 level. Age, smoking, and TOA were independent
predictors of the serum CA-125 level (P = 0.003, 0.013,
and < 0.001, respectively; Table 3). After adjusting for age,
smoking, and the incidence of TOA, a significant differ-
ence in CA-125 level remained between the chlamydia
and non- chlamydia groups (P = 0.001; Fig. 1).
The mean length of hospital stay differed significantly;
it was 8.2 ± 2.7 days for the chlamydia group and 7.2 ±
2.4 days for the non-chlamydia group (P = 0.001). In the
non- chlamydia group, two cases (0.6%) were diagnosed
with FHCS, versus 39.4% of the patients in the chla-
mydia group (P < 0.001). The incidence of surgery was
higher in the chlamydia group (Table 2; 22.2 vs. 9.9%,
respectively; P < 0.001). Although the rate of recurrent
PID was higher in the chlamydia group, the difference
between the two groups was not significant (P = 0.051).
TOA was diagnosed in 13.9% of the patients hospital-
ized for PID (69 of 497). The incidence of TOA was
higher in the chlamydia group than in the non-
chlamydia group (Table 2; 25.7 vs. 7.4%, respectively; P
< 0.001). In the non-chlamydia group, the occurrence of
TOA was associated with IUD insertion, except in one
case.
A ROC curve was constructed and used to select cut-
off values as predictors of chlamydia infection. The
strongest predictor of chlamydia infection was CA-125,
followed by ESR and CRP. The area under the receiving
operating curve (AUC) for CA-125, ESR, and CRP was
0.804, 0.755 and 0.663, respectively (Fig. 2). The cut-off
values for ESR, CRP, and CA-125 are shown in Table 4;
a cut-off value for the leukocyte count was not
determined.
Discussion
Chlamydia infection in the lower genital tract is common
in reproductive-age women, affecting mainly women youn-
ger than 25 years and 20–30% of PID cases have been
attributed to Chlamydia trachomatis [2]. Studies have
proved that chlamydia infection is associated with an in-
creased risk of PID and longer PID hospitalization [19, 20].
Two-thirds of all cases of tubal factor infertility and one-
third of all cases of ectopic pregnancy might be due to chla-
mydia infection [21].
The mechanism of PID in chlamydia infection is not yet
known. Chlamydial heat shock protein 60 expression in-
duced by the cell-mediated immune response drives in-
flammatory responses associated with severe sequelae of
the female reproductive system [22]. A study using non-
human primate models of lower genital tract chlamydia
infection showed chronic salpingitis with extensive tubal
scarring, distal tubal obstruction, and peritubal adhesions
caused by an ascending infection due to cervical inocula-
tion with chlamydia [23].
TOA is one of the most severe complications of PID
and can lead to significant morbidity and occasionally
mortality. TOA is caused by an infection ascending to the
fallopian tube involving aerobes and anaerobes, and tubal
blockage due to tubular endothelial damage and infun-
dibular edema, ovarian invasion by organism through the
site of ovulation, and adhesion formation between the








Mean age (years) 27.9 ± 8.2 32.4 ± 8.3 <0.0001
Married (%) 71 (40.6) 223 (69.3) <0.0001
Parity 0.7 ± 0.9 1.2 ± 1.0 <0.0001
Abortion 1.0 ± 1.2 1.2 ± 1.5 0.36
Cesarean sections (%) 19 (10.9) 89 (27.6) <0.0001
Previous pelvic surgery (%) 35 (20.0) 65 (20.2) 0.530
History of PID 26 (14.9) 61 (18.9) 0.269
Use of IUD (%) 18 (10.3) 38 (11.8) 0.658
Barrier contraceptive use (%) 22 (12.6) 46 (14.3) 0.682
Main symptoms (%)
Low abdominal pain 110 (62.9) 276 (85.7) 0.001
Acute abdomen 19 (10.9) 19 (5.9) 0.321
Vaginal discharge 5 (2.9) 6 (1.9) 0.320
Right upper quadrant pain 34 (19.4) 5 (1.6) <0.0001
Febril sensation 7 (4.0) 16 (5.0) 0.628
Menstrual problem
Menorrhagia (%) 20 (14.0) 15 (9.2) 0.215
Dysmenorrhea (%) 20 (14.0) 15 (9.2) 0.215
Alcohol (%) 72 (41.1) 107 (33.2) 0.096
Smoking (%) 45 (25.7) 74 (22.3) 0.510
PID pelvic inflammatory disease, IUD intrauterine device
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ovary and fallopian tube resulting in the development of
necrosis inside this complex mass, anaerobic growth, and
abscess cavities [24]. An animal study showed that chla-
mydia infection in the lower genital tract facilitates the
formation of abscesses by aerobic and anaerobic bacteria
synergistically [25]. We showed that chlamydia infection
was associated with a higher prevalence of TOA and an
increased risk of surgery in our study.
The diagnosis of PID is based on clinical criteria.
However, given the nonspecific nature of the clinical
diagnosis, several diagnostic tools, including laboratory
tests (e.g., WBC count, ESR, CRP level, and CA-125
level), as well as imaging, endometrial biopsy, and lapar-
oscopy, have been introduced.
CA-125 is a glycoprotein found in the blood that is com-
monly used as a tumor marker of neoplasia because it can
indicate ovarian cancer. CA-125 has been demonstrated in
the peritoneum and epithelial tissues of Müllerian origin in
the female genital tract, such as the endometrium and fallo-
pian tube [26, 27]. Peritoneal irritation such as endometri-
osis, salpingitis, ruptured ectopic pregnancy, and pelvic
surgery often markedly elevates the level of circulating CA-
125, so the serum CA-125 level has been recommended as
a useful test for acute PID [28]. Several studies have found
correlations between the CA-125 level and PID [29, 30].
However, no study has examined the difference in the CA-
125 level in patients with PID according to the presence of
a chlamydia infection. In our study, we found a significant
difference in the CA-125 level between the chlamydia and
non-chlamydia groups.
The increase in serum CA-125 in patients with PID and
a chlamydia infection can be explained in several ways.
First, increased CA-125 levels in endometriosis might be
associated with peritoneal leakage of an endometriotic
cyst and an inflammatory reaction in the mesothelial cells
of the peritoneum [31]. We believe that chlamydia infec-
tions cause more peritoneal irritation than other genital
pathogens. Second, CA-125 antigen is found in normal
adult fallopian tube epithelium, suggesting that severe in-
flammation of the fallopian tube can increase the serum
CA-125 concentration and it is a useful marker for the
clinical diagnosis of salpingitis [29]. It is possible that a
Table 2 Clinical and laboratory data in patients with PID
PID with chlamydia (N = 175) PID without chlamydia (N = 322) P
Mean temperature (°C) 37.2 ± 0.8 37.2 ± 0.9 0.893
Fever (%) 36 (20.6) 73 (22.7) 0.650
Mean WBC count x103/μl 10.3 ± 4.0 10.2 ± 4.5 0.948
Leuocytosis (%) 63 (36.0) 102 (31.7) 0.836
ESR (mm/h) 45.0 ± 26.6 23.5 ± 24.5 <0.0001
CRP (mg/dl) 7.6 ± 7.0 4.8 ± 6.5 <0.0001
CA 125 (U/mL) 130.7 ± 174.6 23.8 ± 40.0 <0.0001
Abnormal CA 125 (%, > 35 U/mL) 115 (65.7) 42 (13.0) <0.0001
Other sexually transmitted infection (%)
Neisseria gonorrhoeae 11(6.3) 1(0.3) <0.0001
Mycoplasma genitalium 13(7.4) 4(1.2) 0.001
Mycoplasma hominis 9 (5.1) 11(3.4) 0.349
Ureaplasma urealyticum 19(10.9) 17(5.3) 0.029
Trichomonas vaginalis 14(8.0) 16(5.0) 0.236
Hospital day (days) 8.2 ± 2.7 7.2 ± 2.4 0.016
Recurrent PID (%) 9 (5.1) 5 (1.6) 0.051
TOA (%) 45 (25.7) 24 (7.4) <0.0001
FHC syndrome (%) 69 (39.4) 2 (0.6) <0.0001
Operation (%) 39 (22.2) 32 (9.9) <0.0001
PID pelvic inflammatory disease, WBC White blood cell, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TOA tubo-ovarian abscess, FHC syndrome
Fitz-Hugh-Curtis syndrome
Table 3 Logistic regression analysis of independent variables
that affect the serum CA-125 level between chlamydia and
non-chlamydia group in acute PID
Variable Odds ratio (95% confidence interval) P
Age -3.00 (-4.073 ~ -0.852) 0.003
Smoking 2.53 (4.032 ~ 20.174) 0.013
TOA 10.84 (129.819 ~ 187.289) <0.0001
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pelvic chlamydia infection causes more severe inflamma-
tion of the fallopian tube than other pelvic infections.
Third, TOA is a major complication of acute PID that is
associated with increased serum CA-125 levels in the
range of neoplastic activity [32].
To our knowledge, our study is among the first to
compare clinical and inflammatory parameters between
chlamydia and non-chlamydia infection in acute PID.
However, our study had several limitations. First, as a
retrospective study, many participants were excluded
from our study because all patients with PID are not
routinely examined for both CA-125 and vaginal swab
for chlamydia. This might lead to selection bias. Second,
the diagnosis of PID in our study was based on the med-
ical history, clinical findings, and elevation of inflamma-
tory markers using the CDC criteria. We did not
perform a laparoscopy or endometrial biopsy to confirm
PID and we failed to confirm the chlamydia infection in
the pelvic organs. Although the clinical symptoms of
PID in combination with one or two inflammatory
parameters can increase the specificity of the diagnosis
of PID, laparoscopy is recommended for confirming the
diagnosis or if there is no improvement within 72 h des-
pite adequate antibiotic therapy [33].
Fig. 1 Mean CA-125 level in chlamydia and non-chlamydia group. After adjustment for age, smoking, and the incidence of TOA, a difference of
CA-125 level between two groups showed a statistical significance (P = 0.001). P value was calculated by analysis of covariance
Fig. 2 ROC curve of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and CA 125 in the diagnosis of chlamydia infection of PID
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Conclusion
In our study, we found that genital chlamydia infection in
acute PID was associated with increased inflammatory
markers such as CA-125 and ESR, higher incidence of
TOA and operation risk, and longer hospitalization. We
need to answer other questions. Do PID and TOA have dif-
ferent mechanisms in genital chlamydia infection? Is there a
correlation between the CA-125 level and severity of PID?
Can we predict TOA or other severe sequelae using the
level of CA-125 or other inflammatory markers? To answer
these questions, additional experimental studies are needed
to determine the mechanism of pelvic inflammation and re-
lated complications caused by a genital chlamydia infection,
and to elucidate the association between the changes in in-
flammatory markers and the severity of infection.
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